Nasal absorption of metoclopramide from different Carbopol® 981 based formulations

Basit Öğe Kaydı
dc.authoridOZKAN, YALCIN/0000-0001-5163-6867
dc.authoridTasdemir, Umut/0000-0003-2827-1286
dc.authoridTAS, Cetin/0000-0001-9004-3239
dc.authoridKOSE OZKAN, Cansel/0000-0002-4340-7279
dc.contributor.authorTas, Cetin
dc.contributor.authorOzkan, Cansel Kose
dc.contributor.authorSavaser, Ayhan
dc.contributor.authorOzkan, Yalcin
dc.contributor.authorTasdemir, Umut
dc.contributor.authorAltunay, Hikmet
dc.date.accessioned2024-09-18T20:33:07Z
dc.date.available2024-09-18T20:33:07Z
dc.date.issued2006
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description4th International Postgraduate Research Symposium on Pharmaceutics (IPORSHIP-2004) -- SEP 20-22, 2004 -- Istanbul, TURKEYen_US
dc.description.abstractThere is a need for nasal drug delivery of metoclopramide HCI (MTC) in specific patient populations where the use of commercially available intravenous and oral dosage forms may be inconvenient and/or unfeasible. In this perspective, nasal dosage forms (solution, gel and lyophilized powder) of MTC were prepared by using a mucoadhesive polymer Carbopol 981 (CRB 981). The drug release studies of formulations were performed by using a modified horizontal diffusion chamber with cellulose membrane and excised cattle nasal mucosa as diffusion barriers. After the ex vivo experiments, the morphological appearances of the nasal mucosa were analyzed with the light microscopic studies. In vivo experiments were carried on sheep model. The release of MTC from solution and powder formulations was found higher than gel formulation (p < 0.05) and no severe damage was found on the integrity of nasal mucosa after ex vivo experiments. The penetration enhancing effect of dimethyl-p-cyclodextrin (DM-beta-CD) used in powder formulations was observed in ex vivo and in vivo experiments. In contrast to in vitro and ex vivo experiments the nasal bioavailability of gel formulation was found higher than those of the solution and powder (p < 0.05) and might represent a promising novel tool for the systemic delivery of MTC. (c) 2006 Elsevier B.V. All rights reserved.en_US
dc.identifier.doi10.1016/j.ejpb.2006.05.017
dc.identifier.endpage254en_US
dc.identifier.issn0939-6411
dc.identifier.issn1873-3441
dc.identifier.issue2en_US
dc.identifier.pmid16870409en_US
dc.identifier.scopus2-s2.0-33748197020en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage246en_US
dc.identifier.urihttps://doi.org/10.1016/j.ejpb.2006.05.017
dc.identifier.urihttps://hdl.handle.net/20.500.12483/11312
dc.identifier.volume64en_US
dc.identifier.wosWOS:000240726800017en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofEuropean Journal of Pharmaceutics and Biopharmaceuticsen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectnasal drug deliveryen_US
dc.subjectmetoclopramideen_US
dc.subjectcarbopol 981en_US
dc.subjectsheepen_US
dc.subjectpowderen_US
dc.subjectDM-beta-CDen_US
dc.titleNasal absorption of metoclopramide from different Carbopol® 981 based formulationsen_US
dc.typeConference Objecten_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
385.2 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu